1. Introduction
===============

Prenatal screening for fetal aneuploidy aims to identify women at increased risk of carrying a fetus with a chromosomal anomaly and limit the offer of invasive diagnostic tests (with their associated risk of miscarriage) to those women at high-risk. National practice guidelines currently recommend that all pregnant women be offered prenatal screening for aneuploidy \[[@B1-jcm-03-00388],[@B2-jcm-03-00388]\]. Methods for prenatal screening have evolved rapidly in recent decades from screening based on maternal age alone, to serum screening, to a combination of maternal serum and ultrasound based measures, and most recently to isolated cell free fetal DNA (cffDNA) from maternal plasma \[[@B3-jcm-03-00388],[@B4-jcm-03-00388],[@B5-jcm-03-00388]\].

Prenatal screening for fetal aneuploidy is most frequently discussed in terms of prenatal screening for trisomy 21 (Down syndrome) as this is the most common form of fetal aneuploidy and this condition has clinical implications for the health of the fetus \[[@B3-jcm-03-00388],[@B4-jcm-03-00388]\]. However, counseling issues arise when anomalies are detected that were not discussed during the informed consent process, given that parents would be unprepared for such a result. Parents consistently report that they do not have enough information about prenatal screening, and may be surprised when they undergo a screening test for trisomy 21 only to find out that their fetus has another (and potentially more severe) anomaly \[[@B6-jcm-03-00388],[@B7-jcm-03-00388],[@B8-jcm-03-00388],[@B9-jcm-03-00388]\]. A good understanding of prenatal screening, prior to accessing this test, is important, because if the results are positive, parents must make important and complex decisions about invasive testing which carries a small, but substantial risk of pregnancy loss, and potentially pregnancy termination \[[@B9-jcm-03-00388],[@B10-jcm-03-00388]\]. Counseling about conditions other than trisomy 21 that may be detected through prenatal screening is complicated for a variety of reasons; the clinical implications of balanced chromosome rearrangements are not always known, the risk of specific anomalies is extremely low, and the reported detection rates and false positive rates for different anomalies vary widely in the literature \[[@B10-jcm-03-00388]\]. This study aimed to systematically review the literature and use diagnostic meta-analysis to derive pooled detection and false positive rates for fetal aneuploidies other than trisomy 21 using standard prenatal screening tests. This information may be helpful to care providers as they discuss the relative strengths and limitations of different forms of prenatal screening with their patients.

2. Methods
==========

2.1. Systematic Review
----------------------

Relevant English-language literature was identified through a systemic search of Medline (1946--2013) and Embase (1974--2013) in November 2013. Reference lists of included articles were examined to identify additional relevant articles that may have been missed in the electronic search. The search terms included generic terms (prenatal diagnosis, antenatal diagnosis, prenatal screening, antenatal screening) as well as specific terms related to the screening test used (first trimester screening, aneuploidy screening, integrated screening, sequential screening, non-invasive prenatal testing, serum screening, combined screening, genetic screening, quad screen) or the chromosomal anomaly (Klinefelter syndrome, tetraploidy, translocation, triploidy, trisomy 13, trisomy 18, Turner syndrome). Truncation symbols were used to include all possible variations of the search term (*i.e.*, screen, screening, screened).

Studies were eligible for inclusion if they provided the data necessary to calculate the number of true positives, false positives, false negatives and true negatives for a chromosomal anomaly other than trisomy 21 using a currently available prenatal screening test (see [Table 1](#jcm-03-00388-t001){ref-type="table"}). Studies that exclusively used maternal serum alpha fetoprotein (MS-AFP) or a combination of MS-AFP and human chorionic gonadotrophin (hCG) (double test) were deemed outdated and were not included in the review. Two reviewers (Amy Metcalfe, Catriona Hippman) independently reviewed all titles and abstracts for potential inclusion. Full-text review was undertaken for any article deemed potentially eligible by either reviewer. Data extraction and verification was performed by the same reviewers. Specific study elements extracted included: screening test used, detection rate, number of women screened, number of screen positive women, number of aneuploid fetuses, study location, and time period of data collection.
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###### 

Prenatal screening tests eligible for inclusion in systematic review.

  Prenatal Screening Test                   Biochemical and Ultrasound Components
  ----------------------------------------- -------------------------------------------------------
  First Trimester Combined Test             NT, PAPP-A, free β hCG
  Second Trimester Triple Screen            AFP, hCG, uE3
  Second Trimester Quadruple Screen         AFP, hCG, uE3, Inhibin A
  Integrated/Sequential/Contingent Screen   (NT, PAPP-A, free β hCG) + (AFP, hCG, uE3, Inhibin A)
  Non-Invasive Prenatal Testing (NIPT)      cffDNA

AFP = alpha-fetoprotein; cffDNA = cell free fetal DNA; hCG = human chorionic gonadatrophin; NT = nuchal translucency; PAPP-A = pregnancy associated plasma protein A; uE3 = unconjugated estriol.

Guidelines for the Meta-analysis of Observational Studies in Epidemiology (MOOSE) \[[@B11-jcm-03-00388]\] and Studies of Diagnostic Accuracy (STARD) \[[@B12-jcm-03-00388]\] were followed.

2.2. Diagnostic Meta-Analysis
-----------------------------

The accuracy of prenatal screening tests is typically evaluated using both the detection rate (sensitivity) and the false positive rate (1-specificity). As these measures are correlated, a bivariate random effects model was used to derive pooled estimates and generate summary receiver operating characteristic (SROC) curves \[[@B13-jcm-03-00388]\]. Studies were weighted based on their total sample size, as large sample sizes allow for more precise estimates of sensitivity and specificity \[[@B14-jcm-03-00388]\]. For a detailed description of the technical specifications of the model, readers are referred to \[[@B14-jcm-03-00388]\]. A minimum of four studies were required to derive pooled detection and false positive rates. All analyses were conducting using Stata 12 SE (StataCorp LP, College Station, TX, USA).

3. Results
==========

Sixty-five articles met all inclusion criteria and were included in the systematic review ([Figure 1](#jcm-03-00388-f001){ref-type="fig"}). Trisomy 18 was the most common aneuploidy eligible for inclusion in the meta-analysis for which literature was available, while the first trimester combined test was the most common prenatal screening test eligible for inclusion in the meta-analysis for which literature was available ([Figure 1](#jcm-03-00388-f001){ref-type="fig"}). Detailed information on all included studies can be found in the [Appendix A](#jcm-03-00388-t005){ref-type="table"}.

![Flow diagram of study selection.](jcm-03-00388-g001){#jcm-03-00388-f001}

3.1. Trisomy 13 (Patau Syndrome)
--------------------------------

Overall, 31 studies reported data on trisomy 13, including 16 studies that utilized the first trimester combined test \[[@B15-jcm-03-00388],[@B16-jcm-03-00388],[@B17-jcm-03-00388],[@B18-jcm-03-00388],[@B19-jcm-03-00388],[@B20-jcm-03-00388],[@B21-jcm-03-00388],[@B22-jcm-03-00388],[@B23-jcm-03-00388],[@B24-jcm-03-00388],[@B25-jcm-03-00388],[@B26-jcm-03-00388],[@B27-jcm-03-00388],[@B28-jcm-03-00388],[@B29-jcm-03-00388],[@B30-jcm-03-00388]\], 8 utilizing the second trimester triple screen \[[@B31-jcm-03-00388],[@B32-jcm-03-00388],[@B33-jcm-03-00388],[@B34-jcm-03-00388],[@B35-jcm-03-00388],[@B36-jcm-03-00388],[@B37-jcm-03-00388],[@B38-jcm-03-00388]\], and 9 using non-invasive prenatal testing (NIPT) \[[@B39-jcm-03-00388],[@B40-jcm-03-00388],[@B41-jcm-03-00388],[@B42-jcm-03-00388],[@B43-jcm-03-00388],[@B44-jcm-03-00388],[@B45-jcm-03-00388]\] ([Table 2](#jcm-03-00388-t002){ref-type="table"} and [Appendix B](#app2-jcm-03-00388){ref-type="app"}). Two studies utilizing NIPT \[[@B39-jcm-03-00388],[@B45-jcm-03-00388]\] included data on two patient groups (a training set and a validation set); hence were included as two distinct studies in the diagnostic meta-analysis.

Substantial variation was noted in the definition of a "screen positive" test for trisomy 13 using the first trimester combined test---definitions for specific risk levels for trisomy 13 included risks ≥1/200 \[[@B19-jcm-03-00388]\], risks of trisomy 13 or 18 ≥1/150 \[[@B15-jcm-03-00388],[@B21-jcm-03-00388]\] or 1/200 \[[@B25-jcm-03-00388]\], or risks of trisomy 13, 18 or 21 ≥1/250 \[[@B24-jcm-03-00388]\] or 1/300 \[[@B23-jcm-03-00388],[@B27-jcm-03-00388]\]. No studies using the second trimester triple screen included a specific risk algorithm for trisomy 13; however, variation in the definition of "screen positive" for trisomy 21 or trisomy 21/trisomy 18 was observed. Studies differed in that some reported cut-off values based on the risk of trisomy 13 at the time of the test (either the first trimester or the second trimester) or at term; however, this only partially explains the differences observed in cut-off values.

NIPT exhibited the strongest overall test performance with a pooled detection rate of 90.3% and a false positive rate \<1% ([Table 2](#jcm-03-00388-t002){ref-type="table"}). The first trimester combined test had a significantly higher detection rate (83.1% *vs.* 43.9%) and a lower false positive rate (4.4% *vs.* 8.1%) than the second trimester triple screen, although statistical significance was not achieved for the false positive rate (*p* \> 0.05) ([Table 2](#jcm-03-00388-t002){ref-type="table"}).
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###### 

Pooled results for trisomy 13.

  Study Characteristics                                                         Prenatal Screening Test                        
  ----------------------------------------------------------------------------- ------------------------- -------------------- ---------------------
  Number of Studies                                                             16                        8                    9
  Number of Patients                                                            245,502                   1,276,894            5840
  Number of Cases                                                               185                       156                  86
  Median prevalence per 10,000 pregnancies (25th--75th percentile range)        5.1 (3.8--16.0)           2.2 (1.2--9.0)       263.2 (71.1--637.8)
  Observed Detection Rates from Included Studies (Minimum-Maximum Range)        0%--100%                  0%--100%             63.6%--100%
  Observed False Positive Rates from Included Studies (Minimum-Maximum Range)   0.1%--12.5%               0.2%--26.1%          0%--1.6%
  Pooled Detection Rate                                                         83.1% (72.6--90.2)        43.9% (23.0--67.2)   90.3% (75.7--96.6)
  Pooled False Positive Rate                                                    4.4% (3.0--6.4)           8.1% (3.1--19.7)     0.2% (0.05--0.8)

3.2. Trisomy 18 (Edward Syndrome)
---------------------------------

Trisomy 18 was the most frequently reported condition in eligible studies. Data was obtained from 61 studies, including 30 that utilized the first trimester combined test \[[@B15-jcm-03-00388],[@B16-jcm-03-00388],[@B17-jcm-03-00388],[@B18-jcm-03-00388],[@B19-jcm-03-00388],[@B20-jcm-03-00388],[@B21-jcm-03-00388],[@B23-jcm-03-00388],[@B24-jcm-03-00388],[@B25-jcm-03-00388],[@B26-jcm-03-00388],[@B27-jcm-03-00388],[@B28-jcm-03-00388],[@B29-jcm-03-00388],[@B30-jcm-03-00388],[@B46-jcm-03-00388],[@B47-jcm-03-00388],[@B48-jcm-03-00388],[@B49-jcm-03-00388],[@B50-jcm-03-00388],[@B51-jcm-03-00388],[@B52-jcm-03-00388],[@B53-jcm-03-00388],[@B54-jcm-03-00388],[@B55-jcm-03-00388],[@B56-jcm-03-00388],[@B57-jcm-03-00388],[@B58-jcm-03-00388],[@B59-jcm-03-00388],[@B60-jcm-03-00388]\], 17 that used the second trimester triple screen \[[@B31-jcm-03-00388],[@B32-jcm-03-00388],[@B33-jcm-03-00388],[@B34-jcm-03-00388],[@B35-jcm-03-00388],[@B36-jcm-03-00388],[@B37-jcm-03-00388],[@B38-jcm-03-00388],[@B61-jcm-03-00388],[@B62-jcm-03-00388],[@B63-jcm-03-00388],[@B64-jcm-03-00388],[@B65-jcm-03-00388],[@B66-jcm-03-00388],[@B67-jcm-03-00388],[@B68-jcm-03-00388],[@B69-jcm-03-00388]\], 12 that contained data on NIPT \[[@B40-jcm-03-00388],[@B41-jcm-03-00388],[@B42-jcm-03-00388],[@B43-jcm-03-00388],[@B44-jcm-03-00388],[@B45-jcm-03-00388],[@B70-jcm-03-00388],[@B71-jcm-03-00388],[@B72-jcm-03-00388],[@B73-jcm-03-00388],[@B74-jcm-03-00388]\], 3 studies that used the second trimester quadruple screen \[[@B47-jcm-03-00388],[@B75-jcm-03-00388],[@B76-jcm-03-00388]\], and 2 studies that reported data on patients undergoing integrated or sequential screening \[[@B52-jcm-03-00388],[@B77-jcm-03-00388]\] ([Table 3](#jcm-03-00388-t003){ref-type="table"} and [Appendix B](#app2-jcm-03-00388){ref-type="app"}). One of the studies reporting on NIPT included data from two separate patient groups \[[@B72-jcm-03-00388]\], and is included as two separate studies in the diagnostic meta-analysis.

Similar to screening for trisomy 13, substantial heterogeneity was observed in the definition for a "screen positive" test for trisomy 18. Positive risk scores for the first trimester combined screen ranged from risks ≥1/100 to ≥1/300. Approximately half of the studies using the second trimester triple screen that reported their definition for "screen positive" results used a patient-specific risk (risks ≥1/100 or ≥1/200), while the remaining studies used a fixed cut-off level based on levels of serum analytes (typically AFP ≤ 0.75 MoM, hCG ≤ 0.55 MoM, and uE3 ≤ 0.60 MoM). Again, studies differed in that some reported cut-off values based on the risk of trisomy 18 at the time of the test (either the first trimester or the second trimester) or at term.
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###### 

Pooled results for trisomy 18.

  Study Characteristics                                                         Prenatal Screening Test                        
  ----------------------------------------------------------------------------- ------------------------- -------------------- ----------------------
  Number of Studies                                                             30                        17                   12
  Number of Patients                                                            325,808                   1,752,184            10,778
  Number of Cases                                                               581                       693                  302
  Median prevalence per 10,000 pregnancies (25th--75th percentile range)        13.9 (8.3--21.3)          4.8 (3.0--22.5)      454.2 (134.8--801.3)
  Observed Detection Rates from Included Studies (Minimum-Maximum Range)        50%--100%                 0%--100%             90%--100%
  Observed False Positive Rates from Included Studies (Minimum-Maximum Range)   0.4%--15.8%               0.2%--35.7%          0%--2.0%
  Pooled Detection Rate                                                         91.9% (85.8--95.6)        70.5% (60.9--78.6)   98.1% (95.1--99.2)
  Pooled False Positive Rate                                                    3.5% (2.5--4.9)           3.3% (3.1--3.6)      0.2% (0.1--0.4)

NIPT exhibited the best overall test performance with a pooled detection rate of 98.1% and false positive rate of \<1% ([Table 3](#jcm-03-00388-t003){ref-type="table"}). The first trimester combined test outperformed the second trimester triple screen, as it had a significantly higher detection rate (91.9% *vs.* 70.5%), with no difference in the false positive rate (*p* \> 0.05) ([Table 3](#jcm-03-00388-t003){ref-type="table"}). There were an insufficient number of studies to derive pooled estimates on the detection rate and false positive rate for trisomy 18 using the second trimester quadruple test, but the observed detection rate ranged from 44.4% to 100% with false positive rates ranging from 0.5% to 9.6% \[[@B47-jcm-03-00388],[@B75-jcm-03-00388],[@B76-jcm-03-00388]\]. Pooled results from the triple screen population may be generalizable to women screened with the quadruple test, as Inhibin A is not part of the trisomy 18 screening protocol.

There were an insufficient number of studies using integrated/sequential screening to determine pooled detection and false positive rates; however, the observed detection rate was 100% in both studies using integrated/sequential screening, while the observed false positive rates ranged from 3.7% to 7.3% \[[@B52-jcm-03-00388],[@B77-jcm-03-00388]\].

3.3. 45,X (Turner Syndrome)
---------------------------

Twenty studies included data on Turner syndrome, 6 that utilized the first trimester combined screen \[[@B19-jcm-03-00388],[@B23-jcm-03-00388],[@B26-jcm-03-00388],[@B30-jcm-03-00388],[@B49-jcm-03-00388],[@B51-jcm-03-00388]\], 9 that used the second trimester triple screen \[[@B31-jcm-03-00388],[@B32-jcm-03-00388],[@B33-jcm-03-00388],[@B34-jcm-03-00388],[@B35-jcm-03-00388],[@B36-jcm-03-00388],[@B66-jcm-03-00388],[@B78-jcm-03-00388],[@B79-jcm-03-00388]\], 4 that involved NIPT \[[@B40-jcm-03-00388],[@B42-jcm-03-00388],[@B43-jcm-03-00388],[@B45-jcm-03-00388]\], and a single study that used the second trimester quadruple screen \[[@B76-jcm-03-00388]\] ([Table 4](#jcm-03-00388-t004){ref-type="table"} and [Appendix B](#app2-jcm-03-00388){ref-type="app"}).
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###### 

Pooled results for 45,X.

  Study Characteristics                                                         Prenatal Screening Test                        
  ----------------------------------------------------------------------------- ------------------------- -------------------- ----------------------
  Number of Studies                                                             6                         9                    4
  Number of Patients                                                            95,159                    1,385,296            1491
  Number of Cases                                                               37                        290                  30
  Median prevalence per 10,000 pregnancies (25th--75th percentile range)        4.2 (2.5--9.3)            3.2 (2.5--6.1)       397.5 (206.9--583.1)
  Observed Detection Rates from Included Studies (Minimum-Maximum Range)        0%--100%                  0%--100%             75%--100%
  Observed False Positive Rates from Included Studies (Minimum-Maximum Range)   4.3%--7.2%                5.1%--26.1%          0%--0.2%
  Pooled Detection Rate                                                         70.1% (51.8--83.7)        77.2% (59.9--88.5)   92.2% (91.6--92.8)
  Pooled False Positive Rate                                                    5.4% (4.7--6.3)           9.3% (6.7--12.8)     0.1% (0.11--0.12)

With the exception of NIPT, none of the other screening tests involved a specific risk cut-off to identify patients at increased risk of carrying a fetus with Turner syndrome. Turner syndrome is considered an incidental finding amongst patients who screen positive for trisomy 13, 18 or 21 with the first trimester combined test and the second trimester triple and quadruple screens. This has implications for the interpretation of test results in a clinical setting.

NIPT had the best overall test performance with a detection rate of 92.2% and a false positive rate of \<0.1% ([Table 4](#jcm-03-00388-t004){ref-type="table"}). A significant difference was not observed between the first trimester combined test and the second trimester triple screen for detection rate, although the first trimester combined test had a significantly lower false positive rate (*p* \< 0.05) ([Table 4](#jcm-03-00388-t004){ref-type="table"}). The single study that used the second trimester quadruple screen had an observed detection rate of 66.7% and a false positive rate of 9.6% \[[@B76-jcm-03-00388]\].

3.4. Triploidy
--------------

Finally, 11 studies provided data on triploidy: 7 of which used the first trimester combined test \[[@B19-jcm-03-00388],[@B20-jcm-03-00388],[@B23-jcm-03-00388],[@B24-jcm-03-00388],[@B27-jcm-03-00388],[@B30-jcm-03-00388],[@B51-jcm-03-00388]\], 3 utilized the second trimester triple screen \[[@B32-jcm-03-00388],[@B33-jcm-03-00388],[@B35-jcm-03-00388]\] and 1 used the second trimester quadruple screen \[[@B76-jcm-03-00388]\]. Triploidy was an incidental finding amongst women who were screen positive for trisomy 13, 18 or 21. This has implications for the interpretation of test results in a clinical setting and how patients should be counseled following a positive screening test.

Seven studies, representing 93,796 women and 15 affected fetuses, contained data on the first trimester combined screen and could be pooled using diagnostic meta-analysis \[[@B19-jcm-03-00388],[@B20-jcm-03-00388],[@B23-jcm-03-00388],[@B24-jcm-03-00388],[@B27-jcm-03-00388],[@B30-jcm-03-00388],[@B51-jcm-03-00388]\]. These studies had a pooled detection rate of 100.0% (99.9--100.0) and a pooled false positive rate of 6.3% (4.9--8.0) ([Appendix B](#app2-jcm-03-00388){ref-type="app"}). Comparable results were also observed for the other screening tests, even though sufficient data were not available to derive pooled estimates. Observed detection rates ranged from 98.1% to 100% with observed false positive rates of 2.6%--10.6% for the second trimester triple screen \[[@B32-jcm-03-00388],[@B33-jcm-03-00388],[@B35-jcm-03-00388]\]; while the single study that used the quadruple screen reported a detection rate of 100% and a false positive rate of 9.6%.

4. Discussion
=============

The results of this systematic review and diagnostic meta-analysis confirm the general consensus that for all conditions, NIPT is a superior test in terms of detection rate and false positive rate than other screening tests for aneuploidies, with the caveat that most studies have been performed in high risk populations. However, NIPT is subject to a higher rate of test failures than other prenatal screening tests and currently only provides results for a limited number of aneuploidies. The dramatically higher median prevalence of aneuploidies used in studies of NIPT to date has important implications on test performance in a low-risk setting. While this is unlikely to impact the overall detection rate and false positive rate, positive predictive values (odds of being affected given a positive result) are particularly sensitive to the prevalence of the condition being studied \[[@B80-jcm-03-00388],[@B81-jcm-03-00388]\]. Additionally, pooled results for NIPT did not display 100% detection rates for any condition, indicating the importance of confirmatory invasive testing. Furthermore, due to the high cost of NIPT, many centers continue to utilize other forms of prenatal screening. Nonetheless, having data on pooled detection rates and false positives rates may be helpful when counseling patients.

Multiple studies have indicated that up to half of the chromosomal anomalies identified through invasive testing for abnormal prenatal screening results or increased maternal age are not autosomal aneuploidies \[[@B15-jcm-03-00388],[@B82-jcm-03-00388],[@B83-jcm-03-00388]\]. Several authors have expressed concern that moving away from serum and ultrasound based screening to prenatal screening based exclusively on NIPT might miss the detection of rare chromosomal anomalies \[[@B5-jcm-03-00388],[@B73-jcm-03-00388],[@B84-jcm-03-00388]\]. Furthermore, extreme levels of serum analytes are associated with adverse obstetrical outcomes and may be useful to help triage patients into higher levels of prenatal care \[[@B85-jcm-03-00388],[@B86-jcm-03-00388],[@B87-jcm-03-00388],[@B88-jcm-03-00388]\]. Contingent screening with NIPT might provide a compromise in terms of maintaining the benefits of existing prenatal screening programs, while reducing the number of women who proceed onto invasive testing, but the current costs of NIPT make this prohibitive to implement in many population-based screening programs. While the costs of NIPT will likely decrease over time, the current cost of NIPT is \$795 (Canadian dollars) in contrast to \$303 for the first trimester combined test and \$15 for the second trimester triple screen \[[@B89-jcm-03-00388],[@B90-jcm-03-00388]\].

Current clinical practice guidelines recommend that prenatal screening should be offered through an informed consent process; in particular, the Society of Obstetricians and Gynecologists of Canada has issued counseling recommendations specifically detailing that all women who are offered prenatal screening should be told that all women have some risk of having a fetus affected by trisomy 21, 18, or 13 \[[@B91-jcm-03-00388]\]. We suggest additional pre-screening counseling recommendations that women should be informed that, while prenatal screening tests have been developed to specifically target the detection of trisomy 21, 18, and 13, other chromosomal anomalies and obstetrical risks may be detected by the screen as well. In particular, it would be worth discussing sex chromosome aneuploidy and triploidy in light of available data, but some mention of the breadth of unexpected results would enhance the informed consent process.

This study has limitations. The search specifically excluded terms related to trisomy 21---this was done on purpose to restrict the number of abstracts identified and because the goal of this review was to look at chromosomal anomalies other than trisomy 21. This may have resulted in some relevant articles not being identified in the initial search; however, the reference lists of accepted articles were hand searched to identify other relevant articles. The quality of the pooled results is a direct reflection of the data included in the original articles; the authors of many studies made the assumption that false negative cases would be brought to their attention through cytogenetic databases or birth certificates and did not actively follow-up all women screened. Additionally, the raw data on true positives, false positives, false negatives and true negatives sometimes had to be back-calculated based on reported detection and false positive rates; this may have resulted in some minor inaccuracies. The model used to generate pooled detection and false positive rates does not specifically account for differences in cut-off values or the specific screening algorithm used to define a positive or negative screening test \[[@B14-jcm-03-00388]\]. However, this is reflected in the different estimates of sensitivity and specificity obtained from individual studies and the heterogeneity of these estimates is directly modeled and used to derive the pooled estimates \[[@B14-jcm-03-00388]\]. Multiple between-study differences were observed in terms of the maternal age distribution, inclusion of pregnancies that ultimately resulted in spontaneous abortion and of multiple gestation pregnancies, test uniformity (specifically related to the use of free β hCG *vs.* total hCG), and test quality standards (specifically related to the use of nuchal translucency). While a random effects model was used to derive pooled estimates, this model addresses statistical heterogeneity, not clinical heterogeneity in the underlying populations. Finally, the search was limited to English language articles which may limit the generalizability of the results. However, the included studies came from North America, Europe, Australia and Asia, indicating wide geographic coverage.

5. Conclusions
==============

In conclusion, while prenatal screening tests are often described to patients in terms of trisomy 21, they do (to varying degrees) identify other chromosomal anomalies. Providing this information to patients prior to screening can help them make an informed choice about accessing prenatal screening and, in some contexts, which screening test is preferable to them.
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###### 

Included studies.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                            Screening Test                      *N*       Detection Rate   False Positive Rate   Cut-Off to Define a Positive Screening Test   Location
  ------------------------------------------------ ----------------------------------- --------- ---------------- --------------------- --------------------------------------------- -----------------------------------------------------------------------------------
  *Trisomy 13*                                                                                                                                                                        

  Alamillo 2013 \[[@B15-jcm-03-00388]\]            First Trimester Combined Test       23,329    100.0            6.3                   T21: 1/300\                                   USA
                                                                                                                                        T13/T18: 1/150                                

  Berktold 2013 \[[@B29-jcm-03-00388]\]            First Trimester Combined Test       14,862    83.3             4.7                                                                 Germany

  Hormansdorfer 2009 \[[@B16-jcm-03-00388]\]       First Trimester Combined Test       2202      0                5.8                   1/230                                         Germany

  Kagan 2008 \[[@B17-jcm-03-00388]\]               First Trimester Combined Test       56,954    93.4             3.1                                                                 UK

  Karadozov-Orlic 2012 \[[@B18-jcm-03-00388]\]     First Trimester Combined Test       4172      81.8             5.3                                                                 Serbia

  Marttala 2011 \[[@B19-jcm-03-00388]\]            First Trimester Combined Test       56,076    54.5             4.5                   T21: 1/250\                                   Finland
                                                                                                                                        T13/T18: 1/200                                

  Merz 2008 \[[@B28-jcm-03-00388]\]                First Trimester Combined Test       40,802    92.3             5.0                                                                 Germany

  Ochshorn 2001 \[[@B26-jcm-03-00388]\]            First Trimester Combined Test       1408      66.7             7.1                                                                 Israel

  Orlandi 1997 \[[@B20-jcm-03-00388]\]             First Trimester Combined Test       2010      50.0             12.5                                                                Italy

  Scott 2004 \[[@B30-jcm-03-00388]\]               First Trimester Combined Test       2053      100.0            7.2                                                                 Australia

  Sorensen 2011 \[[@B21-jcm-03-00388]\]            First Trimester Combined Test       19,694    72.7             1.0                   T21: 1/300\                                   Denmark
                                                                                                                                        T13/T18: 1/150                                

  Spencer 2000 \[[@B22-jcm-03-00388]\]             First Trimester Combined Test       989       83.3             0.1                                                                 England

  Spencer 2000 \[[@B27-jcm-03-00388]\]             First Trimester Combined Test       3762      100.0            6.7                   T13/T18/T21: 1/300                            England

  Spencer 2003 \[[@B23-jcm-03-00388]\]             First Trimester Combined Test       11,105    100.0            5.2                   T13/T18/T21: 1/300                            England

  Stenhouse 2004 \[[@B24-jcm-03-00388]\]           First Trimester Combined Test       5084      100.0            6.2                   T13/T18/T21: 1/250                            Scotland

  Valinen 2012 \[[@B25-jcm-03-00388]\]             First Trimester Combined Test       1000      66.7             4.6                   T13/T18: 1/200                                Finland

  Benn 1996 \[[@B31-jcm-03-00388]\]                Second Trimester Triple Screen      26,364    20.0             8.7                   T21: 1/270\                                   USA
                                                                                                                                        T18: AFP ≤ 0.75 MoM,\                         
                                                                                                                                        Hcg ≤ 0.55 MoM,\                              
                                                                                                                                        uE3 ≤ 0.6 MoM                                 

  Burton 1993 \[[@B32-jcm-03-00388]\]              Second Trimester Triple Screen      8233      0                0.2                   T21: 1/270\                                   USA
                                                                                                                                        T18: AFP ≤ 0.7 MoM,\                          
                                                                                                                                        hCG ≤ 0.5 MoM,\                               
                                                                                                                                        uE3 ≤ 0.55 MoM                                

  Kazerouni 2009 \[[@B33-jcm-03-00388]\]           Second Trimester Triple Screen      752,686   36.0             6.6                   T21: 1/190\                                   USA
                                                                                                                                        T18: 1/100                                    

  Onda 2000 \[[@B34-jcm-03-00388]\]                Second Trimester Triple Screen      32,925    100.0            14.5                  T21: 1/295\                                   Japan
                                                                                                                                        T18: 1/100                                    

  Summers 2003 \[[@B35-jcm-03-00388]\]             Second Trimester Triple Screen      423,895   60.0             9.7                   T21: 1/385 at term\                           Canada
                                                                                                                                        T18: 1/100                                    

  Suzumori 1997 \[[@B37-jcm-03-00388]\]            Second Trimester Triple Screen      1078      50.0             20.3                  T21: 1/299                                    Japan

  Wenstrom 1995 \[[@B36-jcm-03-00388]\]            Second Trimester Triple Screen      1423      0                26.1                  T21: 1/190\                                   USA
                                                                                                                                        T18: AFP ≤ 0.75 MoM,\                         
                                                                                                                                        hCG ≤ 0.55 MoM,\                              
                                                                                                                                        uE3 ≤ 0.6 MoM                                 

  Wortelboer 2008 \[[@B38-jcm-03-00388]\]          Second Trimester Triple Screen      30,290    50.0             13.1                  T21: 1/200\                                   Netherlands
                                                                                                                                        T18: 1/200                                    

  Ashoor 2013 \[[@B39-jcm-03-00388]\]              Non-invasive prenatal testing       156       63.6             0                                                                   England

  Ashoor 2013 \[[@B39-jcm-03-00388]\]              Non-invasive prenatal testing       1949      80.0             0.1                                                                 England and USA

  Bianchi 2012 \[[@B40-jcm-03-00388]\]             Non-invasive prenatal testing       532       78.6             0                                                                   USA

  Chen 2011 \[[@B41-jcm-03-00388]\]                Non-invasive prenatal testing       392       100.0            1.1                                                                 Hong Kong,\
                                                                                                                                                                                      Netherlands,\
                                                                                                                                                                                      UK

  Jiang 2012 \[[@B42-jcm-03-00388]\]               Non-invasive prenatal testing       903       100.0            0                                                                   China

  Lau 2012 \[[@B43-jcm-03-00388]\]                 Non-invasive prenatal testing       108       100.0            0                                                                   Japan

  Palomaki 2012 \[[@B44-jcm-03-00388]\]            Non-invasive prenatal testing       1688      91.7             1.0                   z score ≥ 3                                   Argentina, Australia, Canada, Czech Republic, Hungary, Ireland, Italy, Spain, USA

  Sehnert 2011 \[[@B45-jcm-03-00388]\]             Non-invasive prenatal testing       47        100.0            0                     \>2.5 standard deviations of the mean         USA

  Sehnert 2011 \[[@B45-jcm-03-00388]\]             Non-invasive prenatal testing       65        100.0            1.6                   \>2.5 standard deviations of the mean         USA

  *Trisomy 18*                                                                                                                                                                        

  Alamillo 2013 \[[@B15-jcm-03-00388]\]            First trimester combined test       23,329    100.0            6.3                   T21: 1/300\                                   USA
                                                                                                                                        T13/18: 1/150                                 

  Berktold 2013 \[[@B29-jcm-03-00388]\]            First trimester combined test       14,862    100.0            4.7                                                                 Germany

  Borrell 2004 \[[@B46-jcm-03-00388]\]             First trimester combined test       2765      75.0             3.3                   T21: 1/250                                    Spain

  Breathnach 2007 \[[@B47-jcm-03-00388]\]          First trimester combined test       35,974    82.1             6.0                   T21: 1/150\                                   USA
                                                                                                                                        T18: 1/100                                    

  Centini 2005 \[[@B48-jcm-03-00388]\]             First trimester combined test       408       100.0            15.8                                                                Italy

  Chou 2009 \[[@B49-jcm-03-00388]\]                First trimester combined test       10,811    50.0             5.4                   T21: 1/270                                    Taiwan

  Dhaifalah 2006 \[[@B50-jcm-03-00388]\]           First trimester combined test       686       100.0            5.1                   1/250                                         Czech Republic

  Gaffari 2012 \[[@B51-jcm-03-00388]\]             First trimester combined test       13,706    100.0            4.7                   1/300                                         Iran

  Guanciali-Franchi 2011 \[[@B52-jcm-03-00388]\]   First trimester combined test       7292      66.7             4.2                                                                 Italy

  Hormansdorder 2009 \[[@B16-jcm-03-00388]\]       First trimester combined test       2202      50.0             5.7                   1/230                                         Germany

  Jacques 2007 \[[@B53-jcm-03-00388]\]             First trimester combined test       15,243    66.7             0.4                   T21: 1/300\                                   Australia
                                                                                                                                        T18: 1/250                                    

  Kagan 2008 \[[@B17-jcm-03-00388]\]               First trimester combined test       56,954    96.7             2.4                                                                 UK

  Karadzov-Orlic 2012 \[[@B18-jcm-03-00388]\]      First trimester combined test       4172      85.7             5.3                                                                 Serbia

  Krantz 2000 \[[@B54-jcm-03-00388]\]              First trimester combined test       5718      100.0            0.8                   T18: 1/150                                    USA

  Martinez-Morillo 2012 \[[@B55-jcm-03-00388]\]    First trimester combined test       18,801    100.0            0.4                   1/250                                         Spain

  Marttala 2011 \[[@B19-jcm-03-00388]\]            First trimester combined test       56,076    74.1             4.5                   T21: 1/250\                                   Finland
                                                                                                                                        T13/18: 1/200                                 

  Merz 2008 \[[@B28-jcm-03-00388]\]                First trimester combined test       40,802    94.1             5.0                                                                 Germany

  Ochshorn 2001 \[[@B26-jcm-03-00388]\]            First trimester combined test       1408      66.7             7.1                                                                 Israel

  Orlandi 1997 \[[@B20-jcm-03-00388]\]             First trimester combined test       2010      100.0            12.3                                                                Italy

  Perni 2006 \[[@B56-jcm-03-00388]\]               First trimester combined test       4615      100.0            1.0                                                                 USA

  Scott 2004 \[[@B30-jcm-03-00388]\]               First trimester combined test       2053      100.0            7.2                                                                 Australia

  Sorensen 2011 \[21\]                             First trimester combined test       19,694    91.3             1.5                   T21: 1/300\                                   Denmark
                                                                                                                                        T13/18: 1/150                                 

  Spencer 2000 \[[@B27-jcm-03-00388]\]             First trimester combined test       3762      100.0            6.6                   T13/18/21: 1/300                              England

  Spencer 2003 \[[@B23-jcm-03-00388]\]             First trimester combined test       11,105    100.0            5.1                   T13/18/21: 1/300                              England

  Spencer 2007 \[[@B57-jcm-03-00388]\]             First trimester combined test       521       96.2             1.3                   T21: 1/300\                                   UK
                                                                                                                                        T13/18: 1/100                                 

  Stenhouse 2004 \[[@B24-jcm-03-00388]\]           First trimester combined test       5084      100.0            6.1                   T13/18/21: 1/250                              Scotland

  Tsai 2001 \[[@B58-jcm-03-00388]\]                First trimester combined test       1514      50.0             6.3                   T21: 1/400                                    Taiwan

  Tul 1999 \[[@B59-jcm-03-00388]\]                 First trimester combined test       997       90.0             1.1                                                                 England

  Valinen 2012 \[[@B25-jcm-03-00388]\]             First trimester combined test       1000      73.7             4.6                   T13/18: 1/200                                 Finland

  Wapner 2003 \[[@B60-jcm-03-00388]\]              First trimester combined test       8216      100.0            2.0                   T21: 1/270\                                   USA
                                                                                                                                        T18:1/150                                     

  Barkai 1993 \[[@B61-jcm-03-00388]\]              Second trimester triple screen      5502      66.7             0.3                   T21: 1/300\                                   Israel
                                                                                                                                        T18: 1/100                                    

  Benn 1996 \[[@B31-jcm-03-00388]\]                Second trimester triple screen      26,364    62.5             8.6                   T21: 1/270\                                   USA
                                                                                                                                        T18: AFP ≥ 0.75 MoM,\                         
                                                                                                                                        hCG ≤ 0.55 MoM,\                              
                                                                                                                                        uE3 ≤ 0.6 MoM                                 

  Benn 1999 \[[@B62-jcm-03-00388]\]                Second trimester triple screen      41,565    92.3             0.4                   T21: 1/270\                                   USA
                                                                                                                                        T18: 1/100                                    

  Burton 1993 \[[@B32-jcm-03-00388]\]              Second trimester triple screen      8233      100.0            0.2                   T21: 1/270\                                   USA
                                                                                                                                        T18: AFP ≥ 0.7 MoM,\                          
                                                                                                                                        hCG ≤ 0.5 MoM,\                               
                                                                                                                                        uE3 ≤ 0.55 MoM                                

  Hogge 2001 \[[@B63-jcm-03-00388]\]               Second trimester triple screen      45,145    66.7             0.5                   1/100                                         USA

  Kazerouni 2009 \[[@B33-jcm-03-00388]\]           Second trimester triple screen      752,686   82.5             6.6                   T21: 1/190\                                   USA
                                                                                                                                        T18: 1/100                                    

  Kellner 1995 \[[@B64-jcm-03-00388]\]             Second trimester triple screen      8649      66.7             0.2                   T18: AFP ≥ 0.75 MoM,\                         USA
                                                                                                                                        hCG ≤ 0.55 MoM,\                              
                                                                                                                                        uE3 ≤ 0.6 MoM                                 

  Kishida 2000 \[[@B65-jcm-03-00388]\]             Second trimester triple screen      1055      60.0             35.7                  T21: 1/299 or AFP ≥ 2.5 MoM                   Japan

  McDuffie 1996 \[[@B66-jcm-03-00388]\]            Second trimester triple screen      6197      100.0            0.2                   T21: 1/295\                                   USA
                                                                                                                                        T18: AFP ≥ 0.75 MoM,\                         
                                                                                                                                        hCG ≤ 0.55 MoM,\                              
                                                                                                                                        uE3 ≤ 0.6 MoM                                 

  Meier 2003 \[[@B67-jcm-03-00388]\]               Second trimester triple screen      382,598   62.2             0.2                   1/30 (2nd Trimester) or 1/100 at term         Canada

  Onda 2000 \[[@B34-jcm-03-00388]\]                Second trimester triple screen      32,925    96.4             0.5                   T21: 1/295\                                   Japan
                                                                                                                                        T18: 1/100                                    

  Palomaki 1995 \[[@B68-jcm-03-00388]\]            Second trimester triple screen      10,620    65.2             0.2                                                                 USA

  Summers 2003 \[[@B35-jcm-03-00388]\]             Second trimester triple screen      423,895   52.8             0.2                   T21: 1/385 (at term)\                         Canada
                                                                                                                                        T18: 1/100                                    

  Suzumori 1997 \[[@B37-jcm-03-00388]\]            Second trimester triple screen      1078      0                20.4                  T21: 1/299                                    Japan

  Wenstrom 1995 \[[@B36-jcm-03-00388]\]            Second trimester triple screen      1423      75.0             25.9                  T21: 1/190\                                   USA
                                                                                                                                        T18: AFP ≥ 0.75 MoM,\                         
                                                                                                                                        hCG ≤ 0.55 MoM,\                              
                                                                                                                                        uE3 ≤ 0.6 MoM                                 

  Wenstrom 1997 \[[@B69-jcm-03-00388]\]            Second trimester triple screen      5327      41.7             1.8                   T21: 1/190\                                   USA
                                                                                                                                        T18: AFP ≥ 0.75 MoM,\                         
                                                                                                                                        hCG ≤ 0.55 MoM,\                              
                                                                                                                                        uE3 ≤ 0.6 MoM                                 

  Wortelboer 2008 \[[@B38-jcm-03-00388]\]          Second trimester triple screen      30,290    67.9             13.1                  T21: 1/250\                                   Netherlands
                                                                                                                                        T18: 1/200                                    

  Breathnach 2007 \[[@B47-jcm-03-00388]\]          Second trimester quadruple screen   35,120    100.0            8.9                   T21: 1/300\                                   USA
                                                                                                                                        T18: 1/100                                    

  Jacques 2006 \[[@B75-jcm-03-00388]\]             Second trimester quadruple screen   16,607    44.4             0.5                   T21: 1/250\                                   Australia
                                                                                                                                        T18: 1/200                                    

  Kwon 2012 \[[@B76-jcm-03-00388]\]                Second trimester quadruple screen   9435      100.0            9.6                   T21: 1/270\                                   Korea
                                                                                                                                        T18: 1/100                                    

  Ashoor 2012 \[[@B74-jcm-03-00388]\]              Non-invasive prenatal testing       397       980              0                                                                   UK

  Bianchi 2012 \[[@B40-jcm-03-00388]\]             Non-invasive prenatal testing       532       97.2             0                                                                   USA

  Chen 2011 \[[@B41-jcm-03-00388]\]                Non-invasive prenatal testing       392       91.9             2.0                                                                 Hong Kong,\
                                                                                                                                                                                      Netherlands,\
                                                                                                                                                                                      UK

  Dan 2012 \[[@B70-jcm-03-00388]\]                 Non-invasive prenatal testing       3000      100.0            0.03                                                                China

  Jiang 2012 \[[@B42-jcm-03-00388]\]               Non-invasive prenatal testing       903       100.0            0.1                                                                 China

  Lau 2012 \[[@B43-jcm-03-00388]\]                 Non-invasive prenatal testing       108       90.0             0                                                                   Japan

  Nicolaides 2012 \[[@B73-jcm-03-00388]\]          Non-invasive prenatal testing       1949      100.0            0\.                   Risk ≥1%                                      UK

  Norton 2012 \[[@B71-jcm-03-00388]\]              Non-invasive prenatal testing       3080      97.4             0.1                   1/100                                         USA, Netherlands, Sweden

  Palomaki 2012 \[[@B44-jcm-03-00388]\]            Non-invasive prenatal testing       1971      100.0            0.3                   z score ≥ 3                                   Argentina,\
                                                                                                                                                                                      Australia,\
                                                                                                                                                                                      Canada,\
                                                                                                                                                                                      Czech Republic,\
                                                                                                                                                                                      Hungary,\
                                                                                                                                                                                      Ireland,\
                                                                                                                                                                                      Italy,\
                                                                                                                                                                                      Spain,\
                                                                                                                                                                                      USA

  Sehnert 2011 \[[@B45-jcm-03-00388]\]             Non-invasive prenatal testing       65        100.0            1.6                   \>2.5 standard deviations of the mean         USA

  Sparks 2012 \[[@B72-jcm-03-00388]\]              Non-invasive prenatal testing       167       100.0            0.6                                                                 USA

  Sparks 2012 \[[@B72-jcm-03-00388]\]              Non-invasive prenatal testing       163       100.0            0                                                                   USA

  Benn 2007 \[[@B77-jcm-03-00388]\]                Integrated screening                1203      100.0            7.3                                                                 USA

  Guanciali-Franchi 2011 \[[@B52-jcm-03-00388]\]   Integrated screening                7292      100.0            3.7                   1/250                                         Italy

  *45,X*                                                                                                                                                                              

  Chou 2009 \[[@B49-jcm-03-00388]\]                First trimester combined test       10,811    80.0             5.4                   T21: 1/270                                    Taiwan

  Ghaffari 2012 \[[@B51-jcm-03-00388]\]            First trimester combined test       13,706    100.0            4.7                   1/300                                         Iran

  Marttala 2011 \[[@B19-jcm-03-00388]\]            First trimester combined test       56,076    57.1             4.3                   T21: 1/250\                                   Finland
                                                                                                                                        T13/T18: 1/200                                

  Ochshorn 2001 \[[@B26-jcm-03-00388]\]            First trimester combined test       1408      60.0             7.1                                                                 Israel

  Scott 2004 \[[@B30-jcm-03-00388]\]               First trimester combined test       2053      0                7.2                                                                 Australia

  Spencer 2003 \[[@B23-jcm-03-00388]\]             First trimester combined test       11,105    100.0            5.2                   T13/T18/T21: 1/300                            England

  Benn 1996 \[[@B31-jcm-03-00388]\]                Second trimester triple screen      26,364    75.0             8.7                   T21: 1/270\                                   USA
                                                                                                                                        T18: AFP ≤ 0.75 MoM,\                         
                                                                                                                                        hCG ≤ 0.55 MoM,\                              
                                                                                                                                        uE3 ≤ 0.6 MoM                                 

  Burton 1993 \[[@B32-jcm-03-00388]\]              Second trimester triple screen      8233      60.0             10.6                  T21: 1/270\                                   USA
                                                                                                                                        T18: AFP ≤ 0.7 MoM,\                          
                                                                                                                                        hCG ≤ 0.5 MoM,\                               
                                                                                                                                        uE3 ≤ 0.55 MoM                                

  Kazerouni 2009 \[[@B33-jcm-03-00388]\]           Second trimester triple screen      752,686   79.4             6.6                   T21: 1/190\                                   USA
                                                                                                                                        T18: 1/100                                    

  McDuffie 1996 \[[@B66-jcm-03-00388]\]            Second trimester triple screen      6197      50.0             5.6                   T21: 1/295\                                   USA
                                                                                                                                        T18: AFP ≤ 0.75 MoM,\                         
                                                                                                                                        hCG ≤ 0.55 MoM,\                              
                                                                                                                                        uE3 ≤ 0.6 MoM                                 

  Onda 2000 \[[@B34-jcm-03-00388]\]                Second trimester triple screen      32,925    75.0             14.5                  T21: 1/295\                                   Japan
                                                                                                                                        T18: 1/100                                    

  Ruiz 1999 \[[@B78-jcm-03-00388]\]                Second trimester triple screen      130,595   63.2             5.1                   T21: 1/225                                    USA

  Summers 2003 \[[@B35-jcm-03-00388]\]             Second trimester triple screen      423,895   97.3             9.7                   T21: 1/385 (at term)\                         Canada
                                                                                                                                        T18: 1/100                                    

  Valerio 1996 \[[@B79-jcm-03-00388]\]             Second trimester triple screen      2978      100.0            7.1                   T21: 1/270                                    Italy

  Wenstrom 1995 \[[@B36-jcm-03-00388]\]            Second trimester triple screen      1423      0                26.1                  T21: 1/190\                                   USA
                                                                                                                                        T18: AFP ≤ 0.75 MoM,\                         
                                                                                                                                        hCG ≤ 0.55 MoM,\                              
                                                                                                                                        uE3 ≤ 0.6 MoM                                 

  Kwon 2012 \[[@B76-jcm-03-00388]\]                Second trimester quadruple screen   9435      66.7             9.6                   T21: 1/270\                                   Korea
                                                                                                                                        T18: 1/100                                    

  Bianchi 2012 \[[@B40-jcm-03-00388]\]             Non-invasive prenatal testing       433       93.8             0.2                                                                 USA

  Jiang 2012 \[[@B42-jcm-03-00388]\]               Non-invasive prenatal testing       903       75.0             0.2                                                                 China

  Lau 2012 \[[@B43-jcm-03-00388]\]                 Non-invasive prenatal testing       108       100.0            0                                                                   Japan

  Sehnert 2011 \[[@B45-jcm-03-00388]\]             Non-invasive prenatal testing       47        100.0            0                     \>2.5 standard deviations of the mean         USA

  *Triploidy*                                                                                                                                                                         

  Ghaffari 2012 \[[@B51-jcm-03-00388]\]            First trimester combined test       13,706    100.0            4.8                   1/300                                         Iran

  Marttala 2011 \[[@B19-jcm-03-00388]\]            First trimester combined test       56,076    50.0             4.3                   T21: 1/250\                                   Finland
                                                                                                                                        T13/T18: 1/200                                

  Orlandi 1997 \[[@B20-jcm-03-00388]\]             First trimester combined test       2010      100.0            12.4                                                                Italy

  Scott 2004 \[30\]                                First trimester combined test       2053      100.0            7.2                                                                 Australia

  Spencer 2000 \[[@B27-jcm-03-00388]\]             First trimester combined test       3762      100.0            6.7                   T13/T18/T21: 1/300                            England

  Spencer 2003 \[[@B23-jcm-03-00388]\]             First trimester combined test       11,105    100.0            5.2                   T13/T18/T21: 1/300                            England

  Stenhouse 2004 \[[@B24-jcm-03-00388]\]           First trimester combined test       5084      100.0            6.2                   T13/T18/T21: 1/250                            Scotland

  Burton 1993 \[[@B32-jcm-03-00388]\]              Second trimester triple screen      8233      100.0            10.6                  T21: 1/270\                                   USA
                                                                                                                                        T18: AFP ≤ 0.7 MoM,\                          
                                                                                                                                        hCG ≤ 0.5 MoM,\                               
                                                                                                                                        uE3 ≤ 0.55 MoM                                

  Kazerouni 2009 \[[@B33-jcm-03-00388]\]           Second trimester triple screen      752,686   98.1             6.6                   T21: 1/190\                                   USA
                                                                                                                                        T18: 1/100                                    

  Summers 2003 \[[@B35-jcm-03-00388]\]             Second trimester triple screen      423,895   100.0            9.7                   T21: 1/385 at term\                           Canada
                                                                                                                                        T18: 1/100                                    

  Kwon 2012 \[[@B76-jcm-03-00388]\]                Second trimester quadruple screen   9435      100.0            9.6                   T21: 1/270\                                   Korea
                                                                                                                                        T18: 1/100                                    
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The Summary Receiver Operator Characteristic (SROC) curves below plot the sensitivity (detection rate) of a given test against 1-specificity (false positive rate) of a given test for detecting the condition of interest \[[@B13-jcm-03-00388]\]. Circles represent the point estimate from included studies; the size of the circle is related to the sample size of the study \[[@B13-jcm-03-00388]\]. Diamonds represent the pooled detection rate and false positive rate \[[@B13-jcm-03-00388]\]. The dashed lines represent the 95% confidence region surrounding the pooled effect estimate, while the dotted lines represent the 95% prediction region that would encompass the true detection rate and false positive rates in future studies \[[@B13-jcm-03-00388]\]. The HSROC curve represents the summary receiver operator characteristic curve obtained from the model \[[@B13-jcm-03-00388]\].

![Summary Receiver Operator Characteristic (SROC) Curves for the detection of trisomy 13 using (**A**) first trimester combined test; (**B**) second trimester triple screen; and (**C**) non-invasive prenatal testing.](jcm-03-00388-g002){#jcm-03-00388-f002}

![Summary Receiver Operator Characteristic (SROC) Curves for the detection of trisomy 18 using (**A**) first trimester combined test; (**B**) second trimester triple screen; and (**C**) non-invasive prenatal testing.](jcm-03-00388-g003){#jcm-03-00388-f003}

![Summary Receiver Operator Characteristic (SROC) Curves for the detection of 45,X using (**A**) first trimester combined test; (**B**) second trimester triple screen; and (**C**) non-invasive prenatal testing.](jcm-03-00388-g004){#jcm-03-00388-f004}

![Summary Receiver Operator Characteristic (SROC) Curves for the detection of triploidy using the first trimester combined test.](jcm-03-00388-g005){#jcm-03-00388-f005}
